Athira Pharma Inc expected to post a loss of 71 cents a share - Earnings Preview

LeonaBio

06/11/2024 13:54

* Athira Pharma Inc  ATHA.OQ   ATHA.O  is expected to show
no
change in quarterly revenue when it reports  results on November
7 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Athira Pharma Inc is for
a
loss of 71 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $0.50​, below​ its last closing price of $0.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.74       -0.74      -0.70     Beat    5
 Mar. 31 2024  -0.79       -0.79      -0.69     Beat    12.7
 Dec. 31 2023  -0.98       -0.96      -0.71     Beat    26​
 Jan. 1 0001   -0.82       -0.81      -0.87     Missed  -6.9
 ​​Jun.        -0.79       -0.78      -0.78     Met     0.4
 30 2023                                                
 Mar. 31 2023  -0.62       -0.62      -0.73     Missed  -17​
 Jan. 1 0001               -0.67      -0.53     Beat    20.9
 Sep. 30 2022  -0.65       -0.63      -0.53     Beat    16.3
 This summary was machine generated November 6 at 13:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)